Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Brian M. Stuglik Sells 8,100 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Brian M. Stuglik sold 8,100 shares of the company’s stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $3.39, for a total value of $27,459.00. Following the sale, the director now directly owns 94,958 shares of the company’s stock, valued at $321,907.62. The trade was a 7.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Puma Biotechnology Price Performance

NASDAQ PBYI opened at $3.40 on Friday. The stock has a 50-day simple moving average of $3.22 and a 200 day simple moving average of $3.12. Puma Biotechnology, Inc. has a twelve month low of $2.23 and a twelve month high of $4.13. The stock has a market capitalization of $168.74 million, a PE ratio of 4.42 and a beta of 1.29. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.43 and a current ratio of 1.53.

Wall Street Analyst Weigh In

A number of research firms have recently commented on PBYI. Wall Street Zen raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 22nd. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Friday, February 28th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PBYI. Acorn Capital Advisors LLC bought a new stake in shares of Puma Biotechnology in the fourth quarter valued at approximately $7,475,000. Connor Clark & Lunn Investment Management Ltd. increased its position in Puma Biotechnology by 70.6% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 831,689 shares of the biopharmaceutical company’s stock worth $2,462,000 after acquiring an additional 344,321 shares during the period. Kennedy Capital Management LLC raised its stake in Puma Biotechnology by 36.5% during the 4th quarter. Kennedy Capital Management LLC now owns 809,375 shares of the biopharmaceutical company’s stock valued at $2,469,000 after purchasing an additional 216,329 shares during the last quarter. American Century Companies Inc. boosted its holdings in Puma Biotechnology by 21.2% in the 1st quarter. American Century Companies Inc. now owns 1,149,660 shares of the biopharmaceutical company’s stock valued at $3,403,000 after purchasing an additional 201,284 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Puma Biotechnology by 24.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 863,760 shares of the biopharmaceutical company’s stock worth $2,635,000 after purchasing an additional 170,968 shares during the last quarter. 61.29% of the stock is owned by institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.